

123 - References

References

118 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 Rectal Chlorpromazine suppositories are available from specials manufacturers in the UK in 25mg and 100mg strengths.²¹ The rectal route is not licensed in adults.¹⁷ 100mg given rectally as a suppository is approximately equivalent to 20–25mg chlorpromazine hydrochloride given by IM injection or 40–50mg of chlorpromazine base or hydrochloride given orally.¹⁷ Prochlorperazine suppositories were used successfully short term for the treatment of psychosis in one case report.²² Olanzapine suppositories have been manufactured by a hospital pharmacy and administered for the treatment of delirium or nausea and vomiting in terminally ill patients.²³ References

1. Katare YK, et al. Intranasal delivery of antipsychotic drugs. *Schizophr Res* 2017; 184:2–13.
2. Majcher MJ, et al. In situ-gelling starch nanoparticle (SNP)/O-carboxymethyl chitosan (CMCh) nanoparticle network hydrogels for the intranasal delivery of an antipsychotic peptide. *J Control Release* 2021; 330:738–752.
3. Pandey M, et al. Advances and challenges in intranasal delivery of antipsychotic agents targeting the central nervous system. *Front Pharmacol* 2022; 13:865590.
4. Pires PC, et al. Antipsychotics-loaded nanometric emulsions for brain delivery. *Pharmaceutics* 2022; 14:2174.
5. Miller JL, et al. Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: a pilot pharmacokinetic study. *Pharmacotherapy* 2008; 28:875–882.
6. Cooper I, et al. The pharmacokinetics of intranasal droperidol in volunteers characterised via population modelling. *SAGE Open Med* 2018; 6:2050312118813283.
7. Bleck TP. Dopamine antagonists in ICU delirium. *N Engl J Med* 2018; 379:2569–2570.
8. Smit L, et al. Efficacy of haloperidol to decrease the burden of delirium in adult critically ill patients: the EuRIDICE randomized clinical trial. *Crit Care* 2023; 27:413.
9. Beach SR, et al. Intravenous haloperidol: a systematic review of side effects and recommendations for clinical use. *Gen Hosp Psychiatry* 2020; 67:42–50.
10. Khorassani F, et al. Intravenous olanzapine for the management of agitation: review of the literature. *Ann Pharmacother* 2019; 53:853–859.
11. Wilson IC, et al. A double-blind trial to investigate the effects of Thorazine (Largactil, chlorpromazine), Compazine (Stemetil, prochlorperazine) and Stelazine (trifluoperazine) in paranoid schizophrenia. *J Ment Sci* 1961; 107:90–99.
12. Kostic MA, et al. A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. *Ann Emerg Med* 2010; 56:1–6.

13. Kaminsky BM, et al. Alternate routes of administration of antidepressant and antipsychotic medications. *Ann Pharmacother* 2015; 49:808–817.
14. Karlin DM, et al. Dexmedetomidine sublingual film: a new treatment to reduce agitation in schizophrenia and bipolar disorders. *Ann Pharmacother* 2024; 58:54–64.
15. Citrome L, et al. Sublingual dexmedetomidine for the treatment of acute agitation in adults with schizophrenia or schizoaffective disorder: a randomized placebo-controlled trial. *J Clin Psychiatry* 2022; 83:22m14447.
16. Fernando T, et al. Buccally absorbed vs intravenous prochlorperazine for treatment of migraines headaches. *Acta Neurol Scand* 2019; 140:72–77.
17. National Institute for Health and Care Excellence. British National Formulary (BNF). 2024; <https://bnf.nice.org.uk>.
18. Citrome L, et al. Patches: established and emerging transdermal treatments in psychiatry. *J Clin Psychiatry* 2019; 80:18nr12554.
19. Abruzzo A, et al. Transdermal delivery of antipsychotics: rationale and current status. *CNS Drugs* 2019; 33:849–865.
20. El-Tokhy FSe, et al. Transdermal delivery of second-generation antipsychotics for management of schizophrenia; disease overview, conventional and nanobased drug delivery systems. *J Drug Delivery Sci Technol* 2021; 61:102104.
21. National Health Service UK. dm+d browser. 2024; <https://dmd-browser.nhsbsa.nhs.uk>.
22. Servis M, et al. Treatment of psychosis with prochlorperazine in the ICU setting. *Psychosomatics* 1997; 38:589–590.
23. Matsumoto K, et al. Pharmaceutical studies on and clinical application of olanzapine suppositories prepared as a hospital preparation. *J Pharm Health Care Sci* 2016; 2:20.

Revision #1

Created 2026-01-04 20:12:40 UTC by Omar Ayman

Updated 2026-01-04 20:12:40 UTC by Omar Ayman